I'm a full time value investor and writer who enjoys using classical value ratios to pick my portfolio. Long-term focused on low P/B, P/FCF, Owner Earnings discounting, PEG ratios, the Graham Number and an occasional net-net hunter. I also believe tracking earnings growth versus price appreciation is an essential element to any quality evaluation.I advocate self-indexing primarily using the Dow Jones Industrial Average as my index of choice combined with Joel Greenblatt's Magic Formula. This can help with t ...

文章核心观点 - BOTOX® Cosmetic获得美国FDA批准,可用于改善中度至重度的颌颈连接肌肉带(platysma bands)的外观,这是该产品的第四个适应症[1][2] - 这是首个获批用于改善颌颈连接肌肉带外观的美容神经毒素产品[1][2] - 通过注射BOTOX® Cosmetic可以临时减少下颌线和颈部连接处肌肉的活动,从而改善外观[1] - 临床试验结果显示,大多数患者对BOTOX® Cosmetic治疗后颈部和下颌线条的满意度较高[2] 产品信息 - BOTOX® Cosmetic是目前唯一获批用于4个美容适应症的产品:额头纹、眉间纹、鱼尾纹和颌颈连接肌肉带[1][3][4][5] - 该产品可根据严重程度使用26、31或36单位的剂量进行注射[1] - 该产品的安全性和有效性在临床试验中得到验证[2] 公司信息 - 该产品由Allergan Aesthetics公司(AbbVie公司子公司)开发和销售[6][7] - Allergan Aesthetics公司专注于开发和销售领先的美容品牌和产品[6] - AbbVie公司的使命是开发和提供创新的药物和解决方案,以解决当前的重大健康问题并应对未来的医疗挑战[7] 营销推广 - 患者可通过Allē会员计划了解更多关于BOTOX® Cosmetic治疗颌颈连接肌肉带的信息[3] - Allē是业内首个也是唯一一个为消费者提供在50多个非Allergan Aesthetics品牌和治疗中赢取积分的忠诚度计划[3]

AbbVie (ABBV) announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson's disease (PD). The drug will be marketed under the trade name Vyalev.Vyalev is a solution of carbidopa (CD) and levodopa (LD) prodrugs, which are the standard of care for PD patients. Prodrugs are medications that become active once they enter the body. The drug has been designed to offer continuous subcutaneous delivery of CD/LD prodrugs throug ...

文章核心观点 - 目前市场上存在一些估值较低的优质成长股,值得长期投资[1] - 公司在短期内面临挑战时,投资者应关注其长期发展潜力,而非过于关注短期问题[1] - 三只具有长期投资价值的股票分别是AbbVie、Super Micro Computer和Walt Disney[1] AbbVie - AbbVie拥有多元化的业务,通过收购进一步扩大了业务规模[2] - AbbVie拥有丰富的自由现金流,为未来发展提供了充足的资金支持[2] - 尽管AbbVie的主要产品Humira专利到期对公司造成一定压力,但公司预计未来几年仍能实现高单位数的收入增长[3] - 目前AbbVie股票的估值较低,具有较大的投资价值[3] Super Micro Computer - Super Micro Computer受益于人工智能等新兴技术的发展,销售业绩大幅增长[4] - 但由于一些负面因素的影响,Super Micro Computer股价在短期内出现大幅下跌[4] - 如果Super Micro Computer能够改善毛利率,其股票仍有较大的上涨潜力,目前估值较低[4] Walt Disney - Walt Disney作为顶级品牌,但今年股价表现不佳,主要受主题公园业务疲软的影响[5] - 但Walt Disney的流媒体业务表现较好,已实现盈利,这为公司未来发展带来了积极预期[5] - 尽管短期内经济环境的不确定性可能影响Walt Disney的业绩,但长期来看其仍有较大的投资价值,目前估值较低[6]

The latest trading session saw AbbVie (ABBV) ending at $188.57, denoting a -0.99% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.02%. At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq gained 0.04%.Heading into today, shares of the drugmaker had lost 1.29% over the past month, outpacing the Medical sector's loss of 4.19% and lagging the S&P 500's gain of 3.77% in that time.Investors will be eagerly watching for the performance of AbbVie ...

VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's diseaseAdults treated with VYALEV reported superior improvement in "on" time without troublesome dyskinesia, compared to oral immediate-release carbidopa/levodopa1VYALEV allows for personalized dosing based on individual needs, morning, day and nightNORTH CHICAGO, Ill., Oct. 17, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. ...

A total of 12 abstracts, including four Best of Cosmetic Abstracts, demonstrate Allergan Aesthetics' commitment to patient outcomes and detailed insights and understanding of key concerns across differentiated patient segments Insightful panel discussion with Dr. Kavita Mariwalla, ASDS President Elect (2026) and double board-certified dermatologist, on impact of social media on patient experience and expectations when considering aesthetic treatmentIRVINE, Calif., Oct. 16, 2024 /PRNewswire/ -- Allergan Aest ...

These companies have compelling track records.There are great reasons to follow Warren Buffett's lead and buy stocks with the goal of holding them forever. For instance, there are tax advantages when you hold equities for a long time. Also, when you purchase shares of dividend stocks and opt to reinvest the payouts, the compounding effect can work its magic. Research shows that most of the S&P 500's returns since 1960 can be attributed to reinvested dividends and compounding.Of course, not just any dividend ...

文章核心观点 - 美国医药行业规模在2023年预计达到约5750亿美元,预计到2030年的复合年增长率约为5.5% [1] - 医药行业包括小型生物技术公司和大型制药公司,两者在创新方面存在争议 [1] - 大型制药公司通常拥有盈利历史、股息支付、股票回购等优势 [1] 行业概况 - 医药行业是医疗保健行业的重要组成部分 [1] - 行业包括小型生物技术公司和大型制药公司,两者在创新方面存在争议 [1] - 大型制药公司通常拥有盈利历史、股息支付、股票回购等优势 [1] 个股分析 Merck & Co., Inc. (MRK) - 梅克公司成立超过350年,市值2770亿美元,是全球最大的制药公司之一 [3] - 尽管没有新的重磅药品上市,但公司各业务线表现良好,最新一季度每股收益2.28美元,超出分析师预期 [4] - 相对于同行,梅克公司估值较低,分析师给予其目标价133美元,较当前价格上涨超过20% [4] Johnson & Johnson (JNJ) - 强生公司面临关于其止痒粉产品致癌的长期诉讼,以及药品价格谈判不利影响,过去一年股价仅涨2.8% [6] - 但公司最新一季度销售指引有所上调,主要药品如达雷珠单抗表现良好,预计盈利将温和增长 [7] - 强生公司每股年度股息4.96美元,派息率低于31%,为投资者提供稳定的被动收益 [7] AbbVie Inc. (ABBV) - 艾伯维公司成立仅10余年,但其免疫抑制药物修美乐的专利已过期,但公司其他药品线和丰富管线支撑了营收增长 [8][9] - 公司股息支付已接近四倍,目前股息收益率超过3% [8][9] - 分析师预计公司未来12个月的盈利增长将达到12% [9]

Buying these stocks gives you a great chance to beat the benchmark.The major U.S. stock market indexes are officially in overheated territory thanks to enthusiasm for artificial intelligence (AI). Since the end of 2022, the most popular benchmark, the S&P 500 index, has soared about 51% to a rich valuation that we've not seen since right before some severe market crashes.If we add up earnings from the past 10 years, the average stock in the S&P 500 index is trading at a cyclically adjusted price-to-earnings ...